Search

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To explore the efficacy and safety of berberine-containing quadruple regimen as rescue therapy in H. pylori infected subjects. Methods: Totally 130 patients with H. pylori infection who failed previous first-line eradication therapy were enrolled in this study. The patients were randomly assigned (1:1) 14 d berberine-containing quadruple therapy (berberine 300 mg tid + amoxicillin1000 mg bid + colloidal bismuth tartrate 220 mg bid + esomeprazole 20 mg bid) or 14 d tetracycline-containing quadruple therapy(tetracycline 750 mg bid + furazolidone 100 mg bid + colloidal bismuth tartrate 220 mg bid + esomeprazole 20 mg bid) as second-line rescue treatment. The regularity views were arranged at 14 d and 28 d after treatment,and the symptoms and adverse events were recorded. The eradication status was evaluated by 13C-urea breath test which was performed at least 4 weeks after the end of treatment. Results: Sixty-five patients were assigned to berberine-containing quadruple therapy and 65 patients to tetracycline-containing quadruple therapy. Six patients in berberine-containing quadruple therapy and 4 patients in tetracycline-containing quadruple therapy did not complete treatment because of adverse events. The eradication rates of berberine-containing quadruple therapy and tetracycline- containing quadruple therapy were 76.9 % (50/65) versus 81.5 % (53/65) in intention-to-treat (ITT) analysis (P=0.520) and 84.7 % (50/59) versus 86.9 % (53/61) in per-protocol (PP) analysis (P=0.739), respectively. The overall incidence of adverse events was 49.2 % and 41.5 % (P=0.370), respectively. Conclusions: The 14- day berberine-containing quadruple regimen for Helicobacter pylori infection as second-line therapy can obtain high eradication rate and doesn't increase adverse events obviously, so it is an effective and safe rescue treatment. [ABSTRACT FROM AUTHOR]

Objective: To find out the risk factors of gastric intestinal metaplasia in northwest of China. Methods: A case-control study was conducted with a well-designed questionnaire, all patients were from the clinics of Xijing hospital with the results of gastroscopy and/or gastric mucosal pathology. All patients were enrolled in the present study from August 2014 to April 2015. H. pylori infection was measured by 13C- or 14C-urea breath test or by rapid urease test. Results: A total of 1800 cases were enrolled in the study, among them. 261 cases were with gastric intestinal metaplasia. The multivariate analysis showed that the risk factors of intestinal metaplasia were age ≤60yr (OR, 2.317; 95% CI 1.668-3.220; P< 0.001), H. pylori infection (OR. 2.911; 95% CI 2.339-3.623; P< 0.001), smoking (OR. 2.322; 95% CI 1.553-3.470; P< 0.001), family history of gastric cancer (OR. 2.229; 95% CI 1.444-3.439; P< 0.001). high salt diet (OR. 1.557; 95% CI 1.118-2.168; P=0.009), spicy food (OR. 1.551; 95% CI 1.121-2.147; P=0.005) and bile reflux (OR. 1.851; 95% CI 1.135-3.021: P=0.014). Conclusions: The risk factors of intestinal metaplasia in northwest of China were patients with age ≤60yr, H. pylori infection, smoking, family history of gastric cancer, high salt diet, spicy food and bile reflux. [ABSTRACT FROM AUTHOR]